Gyrasol Technologies Novel TDP-1 Assays in High Throughput Screening

LAWRENCE, Kan. - May 7, 2014 - PRLog -- Scientists at Gyrasol Technologies provided expertise and core technology that enabled workers at the University of Sussex to screen for novel compounds for treatment of chemotherapy drug resistance.  The peer-reviewed work is published in the current issue of Analytical Biochemistry.

The assay was developed in collaboration with scientists at Gyrasol Technologies and the Translational Drug Discovery Group, School of Life Sciences, University of Sussex, Brighton UK, who used Gyrasol’s detection platform technology to develop the robust oligonucleotide screening system, providing a rapid and inexpensive alternative to current methods for screening drugs that act on Tyrosyl-DNA-Phosphodiesterase (TDP) 1 and 2.  The assay is suitable for high-throughput screening of fragment and compound libraries, and can potentially be used to directly test tissues from chemotherapy patients for TDP activity for personalized medicine.  It is commercially available through Gyrasol Technologies Inc.

The Gyrasol detection platform has a number of key features that in combination make it uniquely suitable for drug discovery:

·      rapid and direct

·      activity-based

·      compatible with tissue samples

·      sensitive

·      suitabile for robotic screening

About Gyrasol Technologies

Gyrasol is a private company that offers expert custom assay development services.   A range of commercial enzyme activity assays for drug discovery and systems biology research are provided through distributors including BioVision, Axxora/Enzo, and EMD.